Ryan J. Ellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryan J. Ellis has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Karl Y. Bilimoria
7 shared publicationsMichael G. House
Division of Surgical Oncology, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, United States
6 shared publicationsAnthony D. Yang
5 shared publicationsBrian M. Ruedinger
Department of Surgery, Surgical Outcomes and Quality Improvement Center, Indiana University School of Medicine, Indianapolis, IN, United States
4 shared publicationsThomas K. Maatman
Department of Surgery, Division of Surgical Oncology Indiana University School of Medicine Indianapolis Indiana USA
4 shared publicationsAlexa J. Hughes
Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana School of Medicine, Indianapolis, USA
3 shared publications
Latest Publications
- 21 August 2026
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
Defining Volume Thresholds for Colorectal Cancer Surgery Using Stratum Specific Likelihood Ratios
BACKGROUND: Higher procedure volume correlates with improved surgical outcomes, yet recent literature has questioned whether this relationship persists in modern times. Reports of an attenuated volume-outcome association may reflect the limitations of a single, static, cutoff rather than true weakening of the underlying relationships. Stratum-specific likelihood ratios generate multiple empirically derived volume strata that may detect persistent gradients that are obscured by binary threshold approaches. OBJECTIVES: (1) To define hospital-level volume thresholds for colorectal cancer resections using stratum-specific likelihood ratios, (2) assess these thresholds across multiple outcome measures, procedure types, and tumor locations, and (3) examine whether the volume-outcome relationships persist across temporal cohorts. DESIGN: Retrospective cohort study. SETTING: National Cancer Database from 2004-2020. PATIENTS: Patients undergoing colorectal resection for cancer. Patients with metastatic disease were excluded. MAIN OUTCOME MEASURES: Primary outcome was 90-day mortality. Secondary outcomes included 30-day mortality and textbook outcome (length of stay ≤7 days, negative surgical margin, survival >90 days, and no 30-day readmission). RESULTS: Overall, 1,052,875 patients underwent colorectal resection at 1344 hospitals. Stratum-specific likelihood ratios identified 6 volume strata (≤42, 43-70, 71-108, 109-280, 281-439, and ≥440 colorectal resections per year) with progressively decreasing 90-day mortality across groups (≤42: 5.9% to ≥440: 0.6%). The threshold of 71 resections per year was identified as the optimal threshold. Consistent gradients were also observed across 30-day mortality and textbook outcome and persisted across procedure types and tumor locations. Volume-outcome associations remained significant across all temporal cohorts, including the most recent period (2016-2020; p Video Abstract.
- 21 August 2026
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
Defining Volume Thresholds for Colorectal Cancer Surgery Using Stratum Specific Likelihood Ratios
BACKGROUND: Higher procedure volume correlates with improved surgical outcomes, yet recent literature has questioned whether this relationship persists in modern times. Reports of an attenuated volume-outcome association may reflect the limitations of a single, static, cutoff rather than true weakening of the underlying relationships. Stratum-specific likelihood ratios generate multiple empirically derived volume strata that may detect persistent gradients that are obscured by binary threshold approaches. OBJECTIVES: (1) To define hospital-level volume thresholds for colorectal cancer resections using stratum-specific likelihood ratios, (2) assess these thresholds across multiple outcome measures, procedure types, and tumor locations, and (3) examine whether the volume-outcome relationships persist across temporal cohorts. DESIGN: Retrospective cohort study. SETTING: National Cancer Database from 2004-2020. PATIENTS: Patients undergoing colorectal resection for cancer. Patients with metastatic disease were excluded. MAIN OUTCOME MEASURES: Primary outcome was 90-day mortality. Secondary outcomes included 30-day mortality and textbook outcome (length of stay ≤7 days, negative surgical margin, survival >90 days, and no 30-day readmission). RESULTS: Overall, 1,052,875 patients underwent colorectal resection at 1344 hospitals. Stratum-specific likelihood ratios identified 6 volume strata (≤42, 43-70, 71-108, 109-280, 281-439, and ≥440 colorectal resections per year) with progressively decreasing 90-day mortality across groups (≤42: 5.9% to ≥440: 0.6%). The threshold of 71 resections per year was identified as the optimal threshold. Consistent gradients were also observed across 30-day mortality and textbook outcome and persisted across procedure types and tumor locations. Volume-outcome associations remained significant across all temporal cohorts, including the most recent period (2016-2020; p Video Abstract.
- 24 February 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Long Term and Oncologic Outcomes for Patients Receiving Piperacillin-Tazobactam or Cefoxitin as Antibiotic Prophylaxis for Pancreatoduodenectomy
Objective: To examine long-term and oncologic outcomes of broad-spectrum perioperative antimicrobial prophylaxis, compared with standard care antibiotics, in patients undergoing pancreatoduodenectomy. Background: A registry-linked randomized clinical trial demonstrated a reduction in surgical site infection (SSI) in patients undergoing pancreatoduodenectomy who received piperacillin-tazobactam as perioperative prophylaxis compared to cefoxitin. However, long-term outcomes remain undefined. Methods: Participant records from the American College of Surgeons National Surgical Quality Improvement Program database were matched to the National Cancer Database. Associations between treatment arm, perioperative complications, and oncologic outcomes were assessed. Logistic regression models investigated associations with oncologic outcomes. Survival analyses used Kaplan Meier and Cox proportional hazard modeling. Results: Of 778 patients, 471 (60.5%) were treated at Commission on Cancer accredited hospitals and eligible for linkage. Of those, 426 (90.4%) were matched in the NCDB including 203 (47.7%) treated with piperacillin-tazobactam and 223 (52.3%) with cefoxitin. Among patients with indications for chemotherapy, chemotherapy omission rates were similar between the treatment arms (9.4% in piperacillin-tazobactam vs 15.4% in cefoxitin; P=0.097). There was no association between the receipt of indicated adjuvant chemotherapy and receipt of piperacillin-tazobactam (OR 1.49; 95% CI 0.56-3.95) or presence of SSI (OR 0.58; 95% CI 0.21-1.65). Postoperative SSI was associated with poorer 3-year overall survival (HR 1.69, 95% CI 1.20-2.38). Conclusions: While patients experiencing an SSI had poorer survival, piperacillin-tazobactam prophylaxis did not significantly affect oncologic care delivery. These results cement the long-term implications of perioperative complications in patients with cancer and highlight leveraging cancer registries for clinical trial data analysis
- 24 February 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Long Term and Oncologic Outcomes for Patients Receiving Piperacillin-Tazobactam or Cefoxitin as Antibiotic Prophylaxis for Pancreatoduodenectomy
Objective: To examine long-term and oncologic outcomes of broad-spectrum perioperative antimicrobial prophylaxis, compared with standard care antibiotics, in patients undergoing pancreatoduodenectomy. Background: A registry-linked randomized clinical trial demonstrated a reduction in surgical site infection (SSI) in patients undergoing pancreatoduodenectomy who received piperacillin-tazobactam as perioperative prophylaxis compared to cefoxitin. However, long-term outcomes remain undefined. Methods: Participant records from the American College of Surgeons National Surgical Quality Improvement Program database were matched to the National Cancer Database. Associations between treatment arm, perioperative complications, and oncologic outcomes were assessed. Logistic regression models investigated associations with oncologic outcomes. Survival analyses used Kaplan Meier and Cox proportional hazard modeling. Results: Of 778 patients, 471 (60.5%) were treated at Commission on Cancer accredited hospitals and eligible for linkage. Of those, 426 (90.4%) were matched in the NCDB including 203 (47.7%) treated with piperacillin-tazobactam and 223 (52.3%) with cefoxitin. Among patients with indications for chemotherapy, chemotherapy omission rates were similar between the treatment arms (9.4% in piperacillin-tazobactam vs 15.4% in cefoxitin; P=0.097). There was no association between the receipt of indicated adjuvant chemotherapy and receipt of piperacillin-tazobactam (OR 1.49; 95% CI 0.56-3.95) or presence of SSI (OR 0.58; 95% CI 0.21-1.65). Postoperative SSI was associated with poorer 3-year overall survival (HR 1.69, 95% CI 1.20-2.38). Conclusions: While patients experiencing an SSI had poorer survival, piperacillin-tazobactam prophylaxis did not significantly affect oncologic care delivery. These results cement the long-term implications of perioperative complications in patients with cancer and highlight leveraging cancer registries for clinical trial data analysis
- 30 January 2026
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 30 (4) , 102349
Hospital volume stratification using stratum-specific likelihood ratios for pancreatectomy
- 30 January 2026
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 30 (4) , 102349
Hospital volume stratification using stratum-specific likelihood ratios for pancreatectomy
- Open Access
- 9 December 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 133 (2) , 186-195
Treatment and Outcomes for Patients With Inadequate Lymphadenectomy After Resection of Stage II Small Bowel Adenocarcinoma
Background and Objectives: Adjuvant chemotherapy (AC) is considered for patients with stage II small bowel adenocarcinoma (SBA) with an inadequate lymphadenectomy; however, the prognostic role of additional high‐risk features (T4 primary, positive resection margin, poorly differentiated tumor, or lymphovascular invasion) is unknown. The objectives were to describe utilization of AC among patients with stage II SBA with inadequate lymphadenectomy, identify factors associated with receipt of AC, and examine the association between AC and survival stratified by presence of additional high‐risk features. Methods: Patients with stage II SBA were identified using the National Cancer Database from 2004 to 2021. Inadequate lymphadenectomy was defined < 5 lymph nodes duodenal tumors and < 8 lymph nodes other sites. Results: Of 1765 patients with stage II SBA and an inadequate lymphadenectomy, 525 (29.8%) received AC. T4 primary, poor grade tumor, and positive resection margin were associated with receiving AC. Receipt of AC was associated with improved 5‐year survival in patients with additional high‐risk features (49.9% vs 31.4%; HR 0.62, 95%CI 0.48–0.79) but not in patients without additional high‐risk features (67.1% vs. 53.2%; HR 0.83, 95%CI 0.55–1.24). Conclusions: Receipt of AC was associated with improved survival in patients with inadequate lymphadenectomy and any additional high‐risk feature. Multiple variables may be considered in decisions regarding AC.
- 9 December 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 133 (2) , 186-195
Open AccessTreatment and Outcomes for Patients With Inadequate Lymphadenectomy After Resection of Stage II Small Bowel Adenocarcinoma
Background and Objectives: Adjuvant chemotherapy (AC) is considered for patients with stage II small bowel adenocarcinoma (SBA) with an inadequate lymphadenectomy; however, the prognostic role of additional high‐risk features (T4 primary, positive resection margin, poorly differentiated tumor, or lymphovascular invasion) is unknown. The objectives were to describe utilization of AC among patients with stage II SBA with inadequate lymphadenectomy, identify factors associated with receipt of AC, and examine the association between AC and survival stratified by presence of additional high‐risk features. Methods: Patients with stage II SBA were identified using the National Cancer Database from 2004 to 2021. Inadequate lymphadenectomy was defined < 5 lymph nodes duodenal tumors and < 8 lymph nodes other sites. Results: Of 1765 patients with stage II SBA and an inadequate lymphadenectomy, 525 (29.8%) received AC. T4 primary, poor grade tumor, and positive resection margin were associated with receiving AC. Receipt of AC was associated with improved 5‐year survival in patients with additional high‐risk features (49.9% vs 31.4%; HR 0.62, 95%CI 0.48–0.79) but not in patients without additional high‐risk features (67.1% vs. 53.2%; HR 0.83, 95%CI 0.55–1.24). Conclusions: Receipt of AC was associated with improved survival in patients with inadequate lymphadenectomy and any additional high‐risk feature. Multiple variables may be considered in decisions regarding AC.
- 11 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1653-1654
ASO Visual Abstract: Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma
- 11 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1653-1654
ASO Visual Abstract: Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma
- Open Access
- 16 October 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1576-1585
Association Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma
Background: Surgical care for pancreatic ductal adenocarcinoma (PDAC) is increasingly centralized to high-volume hospitals (HVHs), prompting many patients to travel farther for resection. While surgery is centralized, adjuvant chemotherapy is often delivered locally, resulting in care fragmentation. The implications of this separation on chemotherapy receipt and survival are unclear. This study evaluated associations between travel distance, care fragmentation, and receipt of adjuvant chemotherapy in patients undergoing upfront PDAC resection at HVHs and assessed how these factors influenced overall survival. Methods: Patients with non-metastatic PDAC who underwent upfront resection at HVHs (≥20 pancreatectomies/year) were identified from the National Cancer Database (2007–2021). The cohort was stratified by adjuvant chemotherapy receipt, travel distance (deciles D1–D10), and care fragmentation. Multivariable logistic regression assessed factors associated with chemotherapy receipt; Cox proportional hazards models evaluated survival. Results: Among 17,807 patients treated at 97 HVHs, 10,200 (57%) received adjuvant chemotherapy. Patients traveling ≥14 miles (≥D4) were less likely to receive adjuvant chemotherapy (D4 odds ratio [OR] 0.85; 95% confidence interval [CI] 0.73–0.99; P =0.04). Patients experiencing care fragmentation were more likely to receive adjuvant therapy (64.3% vs. 54.4%, OR 1.51; 95% CI 1.35–1.69; P P =0.01). Conversely, receipt of adjuvant chemotherapy (HR 0.77; 95% CI 0.73–0.81; P P <0.001) were associated with improved survival. Conclusions: Longer travel distance was associated with lower chemotherapy receipt and worse survival. Care fragmentation was linked to improved treatment access and survival, underscoring the need for coordinated cross-institutional care.
- 16 October 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1576-1585
Open AccessAssociation Between Fragmentation of Care and Delivery of Adjuvant Chemotherapy in Patients Traveling to High-Volume Hospitals for Pancreatic Adenocarcinoma
Background: Surgical care for pancreatic ductal adenocarcinoma (PDAC) is increasingly centralized to high-volume hospitals (HVHs), prompting many patients to travel farther for resection. While surgery is centralized, adjuvant chemotherapy is often delivered locally, resulting in care fragmentation. The implications of this separation on chemotherapy receipt and survival are unclear. This study evaluated associations between travel distance, care fragmentation, and receipt of adjuvant chemotherapy in patients undergoing upfront PDAC resection at HVHs and assessed how these factors influenced overall survival. Methods: Patients with non-metastatic PDAC who underwent upfront resection at HVHs (≥20 pancreatectomies/year) were identified from the National Cancer Database (2007–2021). The cohort was stratified by adjuvant chemotherapy receipt, travel distance (deciles D1–D10), and care fragmentation. Multivariable logistic regression assessed factors associated with chemotherapy receipt; Cox proportional hazards models evaluated survival. Results: Among 17,807 patients treated at 97 HVHs, 10,200 (57%) received adjuvant chemotherapy. Patients traveling ≥14 miles (≥D4) were less likely to receive adjuvant chemotherapy (D4 odds ratio [OR] 0.85; 95% confidence interval [CI] 0.73–0.99; P =0.04). Patients experiencing care fragmentation were more likely to receive adjuvant therapy (64.3% vs. 54.4%, OR 1.51; 95% CI 1.35–1.69; P P =0.01). Conversely, receipt of adjuvant chemotherapy (HR 0.77; 95% CI 0.73–0.81; P P <0.001) were associated with improved survival. Conclusions: Longer travel distance was associated with lower chemotherapy receipt and worse survival. Care fragmentation was linked to improved treatment access and survival, underscoring the need for coordinated cross-institutional care.